Verastem Inc. (VSTM)
NASDAQ: VSTMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VSTM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $797.67M
- EPS (TTM)
- -$1.84
- Dividend yield
- None
- 52-week range
- 3.43 – 10.82
- Day range
- 6.25 – 6.82
- Volume / Avg
- 3.24M / 3.53M
- Beta
- —
- Shares outstanding
- 126.01M
52-week range
VSTM stock today
Verastem (VSTM) closed at $6.33 on Nov 20, down 7.73% (-$0.53), versus the S&P 500's 3.70% decline. At this level, VSTM sits in the middle of its 52-week range of $3.43 to $10.82: 41.5% below the high, set on Nov 26, 2025 and 84.5% above the low. VSTM is down 18.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 36.7%.
Verastem has posted a net loss over the last twelve months (EPS of -$1.84), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Verastem
Company profileVerastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Daniel W. Paterson
- Headquarters
- Needham, MA
- Employees
- 102
- IPO year
- 2012
- Website
- verastem.com
Financial highlights
Full financialsIn fiscal 2025, Verastem generated $30.9 million in revenue, up 209.1% from fiscal 2024. Verastem reported a net loss of $209.5 million, compared with a loss of $130.6 million a year earlier. Operating margin was -550.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $30.91M | $10.00M | — | $2.60M | $2.05M |
| Growth | +209.14% | — | — | +26.45% | -97.68% |
| Net income | $-209.47M | $-130.64M | $-87.37M | $-73.81M | $-71.20M |
| EPS (diluted) | $-3.02 | $-3.66 | $-3.96 | $-4.57 | $-4.90 |
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$17.22+172.04%
- Strong buy 1
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-1.35 vs $-0.44
- Surprise
- -206.82%
VSTM news
All VSTM news- Verastem (VSTM) Q3 2026 Earnings Call TranscriptNasdaq
- Verastem expects october financing and CO-PACK revenue to fund operations into first half of 2028Seeking Alpha
- Verastem Non-GAAP EPS of -$0.72 misses by $0.28, revenue of $24.01M misses by $2.07MSeeking Alpha
- Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business UpdatesBusiness Wire
- Verastem Consensus Price Target Increased by 17.42% to $17.57Nasdaq
- Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026Business Wire
- Why is Verastem stock surging today?Investing.com
- Verastem Oncology Prices $250 Mln Stock, Warrant Offering; Pre-market Shares UpNasdaq
Verastem peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SNDXSyndax Pharmaceuticals Inc. | 8.72 | -4.49% | $785.05M | vs VSTM |
| CRVSCorvus Pharmaceuticals Inc. | 9.67 | -3.40% | $815.69M | vs VSTM |
| PHARPharming Group N.V. ADS | 11.54 | -5.10% | $816.78M | vs VSTM |
| IRWDIronwood Pharmaceuticals Inc. Class A | 4.70 | -0.21% | $778.09M | vs VSTM |
| COLLCollegium Pharmaceutical Inc. | 24.72 | -1.94% | $768.18M | vs VSTM |
| ORICOric Pharmaceuticals Inc. | 7.36 | -4.42% | $764.94M | vs VSTM |
| RIGLRigel Pharmaceuticals Inc. | 40.09 | -2.67% | $754.89M | vs VSTM |
| ARDXArdelyx Inc. | 2.99 | -2.29% | $751.60M | vs VSTM |
Indexes, lists and sector
Verastem stock FAQ
What is Verastem's stock price today?
VSTM last traded at $6.33 as of Nov 20, 4:00 PM EST, down 7.73% on the day. Prices are delayed at least 15 minutes.
Does Verastem pay a dividend?
No. Verastem does not currently pay a regular cash dividend.
Who is Verastem's CEO?
Mr. Daniel W. Paterson is the chief executive officer of Verastem Inc., which has about 102 employees.
Has VSTM ever split its stock?
Yes. The most recent VSTM stock split was a 1-for-12 split on Jun 1, 2023.
What is the VSTM 52-week high?
The 52-week high for VSTM is $10.82 and the 52-week low is $3.43. The stock is currently 41.5% below its high.